OLMA Olema Pharmaceuticals, Inc.

CIK 0001750284 50 ready 8-Ks latest August 10, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing October 15, 2026, 5:00 PM ET

Top materiality 0.80

Event mix other_material ×22 · earnings ×13 · other ×8

Sentiment 19 pos · 1 neg · 30 neu

Latest earnings ▲ beat 2026-Q1

Executive change recent →

Recent 8-K filings for OLMA

Highest-materiality recent filing

Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M

December 2, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.
$250M private placement: 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares; gross proceeds ~$250M, closing expected Dec 4, 2024.

Read filing →

August 10, 2026, 4:05 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Olema Q2 2026 net loss $63.2M, cash $461.1M; OPERA-01 enrollment complete

Net loss $63.2M vs $43.8M in Q2 2025; R&D expenses $57.8M vs $43.9M (GAAP).
May 21, 2026, 5:05 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Olema announces Phase 1 data for OP-3136: tumor shrinkage in 13/19 evaluable, no DLTs

OP-3136 monotherapy well-tolerated up to 45 mg; no DLTs, no discontinuations due to TRAEs.
March 16, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026

Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.
November 19, 2025, 6:59 PM ET other material materiality 0.65 neutral item 8.01 item 9.01

Olema Pharmaceuticals announces $190M follow-on offering of 10M shares at $19.00

Offering of 10,000,000 shares of common stock at $19.00 per share for gross proceeds of ~$190M.
October 20, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema reports palazestrant + ribociclib Phase 1b/2 mPFS of 15.5 months in ER+/HER2- MBC

As of July 8, 2025, 72 patients enrolled across 90 mg and 120 mg palazestrant dose cohorts with ribociclib 600 mg.
September 2, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2

Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.
August 11, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M

Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.
May 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months

Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.
December 10, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema gets FDA IND clearance for OP-3136; palazestrant combo shows 73% 6-month PFS

FDA cleared IND for KAT6 inhibitor OP-3136; Phase 1 to start early 2025.
December 2, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M

Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.
November 12, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track

Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).
September 27, 2024, 7:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025

Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.
August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Olema Q2 net loss $30.4M; cash $239.1M; palazestrant combo shows 85% CBR

Net loss for Q2 2024 was $30.4M vs $20.1M in Q2 2023, driven by increased R&D spending on late-stage trials.
July 2, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03

Olema Pharmaceuticals amends loan facility, ups potential borrowing to $100M, extends maturity to 2028

Borrowing capacity increased from $50M to up to $100M with $25M immediately available.
May 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC

Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.
May 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Olema reports Q1 net loss of $31.0M; cash $249M; enrollment complete in two palazestrant combo studies

Net loss of $31.0M for Q1 2024 vs $28.3M a year ago; cash & equivalents $249.0M.
March 11, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Olema reports FY2023 net loss $96.7M, cash $261.8M; palazestrant Phase 3 underway

Cash, equivalents and marketable securities $261.8M as of Dec 31, 2023; net loss $96.7M for FY2023 vs $104.8M in FY2022.
January 5, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Olema Pharmaceuticals enters $150M ATM equity offering with TD Cowen, terminates prior Oppenheimer ATM

Enters ATM agreement with Cowen and Company (TD Cowen) to sell up to $150M of common stock at market prices.
December 5, 2023, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema reports positive Phase 1b/2 combo data for palazestrant; Phase 3 OPERA-01 enrolling

Palazestrant + ribociclib (19 patients) well-tolerated; no dose-limiting toxicities, no drug-drug interaction.
November 7, 2023, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01 ◈ Earnings Releases

Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track

Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.
October 23, 2023, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Olema reports Phase 2 palazestrant results: median PFS 4.6 mo in all patients; 7.2 mo in 2nd/3rd-line subset

Palazestrant (OP-1250) median PFS of 4.6 months (CBR 40%) in 86 heavily pretreated metastatic ER+/HER2- breast cancer patients.
October 17, 2023, 7:59 PM ET leadership materiality 0.60 positive item 1.01 item 7.01 item 9.01

Olema appoints Scott Garland to Board; brings commercial expertise for late-stage palazestrant development

Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.
October 10, 2023, 7:59 PM ET other material materiality 0.60 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Olema and Novartis expand Phase 1/2 combo study of palazestrant + ribociclib to ~60 patients

Amendment adds ~30 patients to dose expansion, increasing study size to about 60 total.
September 5, 2023, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 2.03 item 3.02 item 9.01 ◈ Material Agreements ×2

Olema raises $130M equity, secures $50M credit facility from SVB

Private placement of 13,211,382 shares at $9.84/share raises ~$130M gross.
August 8, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023

Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.
May 11, 2023, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC

Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.
May 9, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Olema Pharma Q1 net loss $28.3M, cash $186M; Phase 3 trial of OP-1250 planned H2 2023

Cash, cash equivalents and marketable securities of $186.0M as of March 31, 2023, expected to fund operations into 2025.
March 10, 2023, 6:59 PM ET other material materiality 0.60 positive item 7.01

Olema confirms no cash deposits or securities at Silicon Valley Bank

Company holds zero cash or securities at Silicon Valley Bank.

Executive changes

Departed

Gorjan Hrustanovic

Director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2026-10-14
Filed: October 15, 2026, 5:00 PM ET

On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective October 14, 2026. Dr. Hrustanovic also resigned from the Compensation Committee of the Board (the “Compensation Committee”) and the Science and Technology Committee of the Board (the “Science and Technology Committee”). Dr. Hrustanovic’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Appointed

Prakash Raman

Class II director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2026-04-28
Filed: April 29, 2026, 7:59 PM ET

the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026

Appointed

Scott Garland

Class III Director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2023-10-16
Filed: October 18, 2023, 7:59 PM ET

appointed Scott Garland to the Board as a Class III director, effective October 16, 2023

Role change

Peter Kushner

Senior Research Fellow and Co-Founder

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2022-04-01
Filed: March 14, 2022, 7:59 PM ET

On March 10, 2022, Peter Kushner, Ph.D., Chief Scientific Officer (“CSO”) of Olema Pharmaceuticals, Inc. (the “Company”), and the Company agreed that Dr. Kushner would transition from CSO to Senior Research Fellow and Co-Founder, a non-executive role, effective April 1, 2022.

Earnings & guidance

2026-Q1 EPS reported -$0.52 vs consensus -$0.54 ▲ beat (+3.6%) filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event other_material

19 positive 1 negative 30 neutral

source · OLMA on sec.gov